At a glance
- Originator Pharmacia Corporation
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatic disorders
Most Recent Events
- 31 Oct 1995 Discontinued-II for Inflammatory bowel disease in Japan (Unknown route)
- 31 Oct 1995 Discontinued-II for Psoriasis in Japan (Unknown route)
- 31 Oct 1995 Discontinued-II for Rheumatic disorders in Japan (Unknown route)